Nolvadex D (Tamoxifen Citrate)

Tamoxifen citrate acts as a competitive antagonist at estrogen receptors in breast tissue, blocking estrogen‑driven tumor cell growth. It also shows partial agonist activity in bone and uterine tissue, helping maintain bone density while still inhibiting cancer proliferation.

The specific dose of Nolvadex D is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, and individual health factors. Dosage regimens are tailored to each patient and should follow the prescriber’s instructions.

Tamoxifen citrate is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nolvadex D belongs to the selective estrogen receptor modulator class, differing from aromatase inhibitors and chemotherapy agents. While aromatase inhibitors lower overall estrogen levels, tamoxifen blocks estrogen receptors directly, offering an oral option with a distinct side‑effect profile and suitability for pre‑menopausal patients.

Nolvadex D should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight, and excessive heat to maintain potency throughout its shelf life.

Nolvadex D is taken orally, usually as a tablet swallowed with water. The exact frequency and duration are prescribed by the treating physician and may vary according to the indication and patient response.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, endometrial cancer, severe liver toxicity, and life‑threatening allergic reactions. Patients should be monitored regularly for signs of these conditions and report any concerning symptoms promptly.

Nolvadex D is contraindicated in patients with a known hypersensitivity to tamoxifen or any of its excipients, in pregnant women, and in individuals with active thromboembolic disease or uncontrolled liver disease. Clinicians should evaluate each patient’s medical history before initiating therapy.